Announcements
- Delårsrapport för januari – mars 2024
- Interim Report - January-March 2024
- Aktieägarna i Karolinska Development AB (publ) kallas till årsstämma
- Notice of Annual General Meeting in Karolinska Development AB (publ)
- Karolinska Developments portföljbolag Umecrine Cognition presenterar positiva säkerhetsdata från första delen av bolagets fas 1b/2-studie i PBC
- Karolinska Development’s portfolio company Umecrine Cognition presents positive safety data from the first part of its Phase 1b/2 study in PBC
- Karolinska Developments årsredovisning för 2023 har publicerats
- Karolinska Development Annual Report 2023 published
- Karolinska Development’s portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million
- Karolinska Developments portföljbolag Aprea Therapeutics får IND-godkännande från FDA och säkrar finansiering om USD 34 miljoner
More ▼
Key statistics
On Wednesday, Karolinska Development AB (0P3C:LSE) closed at 1.54, 5.82% above its 52-week low of 1.46, set on Nov 01, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 1.54 |
Average volume | 387.67 |
---|---|
Shares outstanding | 267.52m |
Free float | 94.80m |
P/E (TTM) | 12.69 |
Market cap | 422.69m SEK |
EPS (TTM) | 0.1245 SEK |
Data delayed at least 20 minutes, as of Apr 24 2024 17:40 BST.
More ▼